

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



信銘生命科技集團有限公司
Aceso Life Science Group Limited

(formerly known as Hao Tian Development Group Limited 昊天發展集團有限公司)
(Incorporated in Cayman Islands with limited liability)
(Stock Code: 00474)

PROFIT WARNING

This announcement is made by Aceso Life Science Group Limited (formerly known as Hao Tian Development Group Limited) (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company wishes to inform the shareholders of the Company and the potential investors that, based on the latest available unaudited financial information of the Group for the six months ended 30 September 2020 (the “**Period**”), the Group expects to record a loss of approximately HK\$460 million for the Period as compared to the loss of approximately HK\$64 million for the corresponding period in 2019.

The loss for the Period was mainly attributable to the recognition of expected credit losses on corporate notes and loan receivables; a one-off non-cash share-based payment expense in relation to the grant of share options in June 2020; and fair value losses on certain financial assets and liabilities at fair value through profit or loss.

The information contained in this announcement is only based on the assessment on the financial information currently available, which is subject to adjustments and has not been finalised and reviewed by the audit committee of the Company. The Company is still in the course of finalising the interim results. The interim results announcement of the Group for the Period is expected to be published by the end of November 2020 and the actual results of the Group may be different from what disclosed herein.

By order of the board of directors of
Aceso Life Science Group Limited
Fok Chi Tak
Executive Director

Hong Kong, 9 November 2020

As at the date of this announcement, the board of directors of the Company comprises three executive directors, namely Mr. Xu Haiying, Dr. Zhiliang Ou, J.P. (Australia) and Mr. Fok Chi Tak; two non-executive directors, namely Dr. Wang Yu and Dr. Li Yao; and three independent non-executive directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Lee Chi Hwa, Joshua.